Until the three ongoing randomised controlled trials of preventive therapy are completed, there remains a large knowledge gap about how individuals known to have been exposed to multidrug-resistant TB (MDR-TB) should be managed. The evolving paradigms and improving outcomes from treatment of active MDR-TB disease play in to discussions about the relative merits and importance of intensive surveillance and/or preventive therapy for MDR-TB contacts
The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampi...
BackgroundMultidrug-resistant tuberculosis (MDR TB) is more difficult to treat and outcomes are wors...
After years of steady decline, there has been an unprecedented resurgence of tuberculosis (TB) in th...
Until the three ongoing randomised controlled trials of preventive therapy are completed, there rema...
The diagnosis of multidrug resistant tuberculosis (MDR-TB) in any individual is the beginning of a p...
CITATION: Gupta, A. et al. 2020. Feasibility of identifying household contacts of rifampin-and multi...
Of the estimated half a million people who develop multidrug resistant (MDR) tuberculosis each year,...
Of the 10 million incident cases of tuberculosis (TB) globally in 2017, around 558,000 cases were ri...
Demers, A. M., et al. 2021. Drug susceptibility patterns of Mycobacterium tuberculosis from adults w...
Multidrug-resistant tuberculosis (MDR-TB) caused by Mycobacterium tuberculosis resistant to both iso...
Drug Resistance is a major challenge in the control of Tuberculosis which itself remains a global pu...
Setting: The effectiveness of public health strategies following exposure to multidrug-resistant tub...
SummaryTuberculosis (TB) is a major infectious disease killing nearly two million people, mostly in ...
Multidrug-resistant tuberculosis (MDR TB) is a significant threat to global health estimated to acco...
Multidrug-resistant TB (MDR-TB) is a major threat to global health. In 2017, only 50% of patients wi...
The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampi...
BackgroundMultidrug-resistant tuberculosis (MDR TB) is more difficult to treat and outcomes are wors...
After years of steady decline, there has been an unprecedented resurgence of tuberculosis (TB) in th...
Until the three ongoing randomised controlled trials of preventive therapy are completed, there rema...
The diagnosis of multidrug resistant tuberculosis (MDR-TB) in any individual is the beginning of a p...
CITATION: Gupta, A. et al. 2020. Feasibility of identifying household contacts of rifampin-and multi...
Of the estimated half a million people who develop multidrug resistant (MDR) tuberculosis each year,...
Of the 10 million incident cases of tuberculosis (TB) globally in 2017, around 558,000 cases were ri...
Demers, A. M., et al. 2021. Drug susceptibility patterns of Mycobacterium tuberculosis from adults w...
Multidrug-resistant tuberculosis (MDR-TB) caused by Mycobacterium tuberculosis resistant to both iso...
Drug Resistance is a major challenge in the control of Tuberculosis which itself remains a global pu...
Setting: The effectiveness of public health strategies following exposure to multidrug-resistant tub...
SummaryTuberculosis (TB) is a major infectious disease killing nearly two million people, mostly in ...
Multidrug-resistant tuberculosis (MDR TB) is a significant threat to global health estimated to acco...
Multidrug-resistant TB (MDR-TB) is a major threat to global health. In 2017, only 50% of patients wi...
The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampi...
BackgroundMultidrug-resistant tuberculosis (MDR TB) is more difficult to treat and outcomes are wors...
After years of steady decline, there has been an unprecedented resurgence of tuberculosis (TB) in th...